Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)-Reference-Cited by-同舟云学术

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Published:2022-07-23 Issue:9 Volume:113 Page:3169-3179
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Yamamoto Yutaka¹^ORCID,Iwata Hiroji²,Taira Naruto³^ORCID,Masuda Norikazu⁴^ORCID,Takahashi Masato⁵^ORCID,Yoshinami Tetsuhiro⁶⁷,Ueno Takayuki⁸^ORCID,Toyama Tatsuya⁹^ORCID,Yamanaka Takashi¹⁰,Takano Toshimi¹¹¹²,Kashiwaba Masahiro¹³¹⁴,Tsugawa Koichiro¹⁵,Hasegawa Yoshie¹⁶,Tamura Kenji¹⁷¹⁸^ORCID,Tada Hiroshi¹⁹,Hara Fumikata¹²²⁰,Fujisawa Tomomi²¹,Niikura Naoki²²,Saji Shigehira²³,Morita Satoshi²⁴,Toi Masakazu²⁵^ORCID,Ohno Shinji²⁶

Affiliation:

1. Department of Breast and Endocrine Surgery Kumamoto University Hospital Kumamoto Japan

2. Department of Breast Oncology Aichi Cancer Center Hospital Nagoya Japan

3. Department of Breast and Endocrine Surgery Okayama University Hospital Okayama Japan

4. Department of Breast and Endocrine Surgery Nagoya University Graduate School of Medicine Nagoya Japan

5. Department of Breast Surgery National Hospital Organization Hokkaido Cancer Center Sapporo Japan

6. Department of Medical Oncology Osaka International Cancer Institute Osaka Japan

7. Department of Breast and Endocrine Surgery, Graduate School of Medicine Osaka University Osaka Japan

8. Breast Surgical Oncology, Breast Oncology Center The Cancer Institute Hospital of the JFCR Tokyo Japan

9. Department of Breast Surgery Nagoya City University Graduate School of Medical Sciences Nagoya Japan

10. Department of Breast and Endocrine Surgery Kanagawa Cancer Center Yokohama Japan

11. Department of Medical Oncology Toranomon Hospital Tokyo Japan

12. Breast Medical Oncology, Breast Oncology Center The Cancer Institute Hospital of JFCR Tokyo Japan

13. Department of Breast Surgery, Social Medical Corporation Hakuaikai Sagara Hospital Kagoshima Japan

14. Department of Breast Surgery Adachi Breast Clinic Kyoto Japan

15. Department of Surgery St. Marianna University School of Medicine Kawasaki Japan

16. Department of Breast Surgery Hirosaki Municipal Hospital Aomori Japan

17. Department of Breast and Medical Oncology National Cancer Center Hospital Tokyo Japan

18. Department of Medical Oncology Shimane University Hospital Izumo Japan

19. Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine Tohoku University Sendai Japan

20. Department of Breast Oncology National Hospital Organization Shikoku Cancer Center Matsuyama Japan

21. Department of Breast Oncology Gunma Prefectural Cancer Center Ota Japan

22. Department of Breast Oncology Tokai University Hospital Isehara Japan

23. Department of Medical Oncology Fukushima Medical University School of Medicine Fukushima Japan

24. Department of Biomedical Statistics and Bioinformatics Kyoto University Graduate School of Medicine Kyoto Japan

25. Department of Breast Surgery Kyoto University Graduate School of Medicine Kyoto Japan

26. Breast Oncology Center The Cancer Institute Hospital of the JFCR Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15474

Reference35 articles.

1. The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition

2. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Clinical Practice Guideline Update Summary

3. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

4. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

5. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives;Nature Reviews Clinical Oncology;2024-01-08

2. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS);BMC Pharmacology and Toxicology;2023-11-13

3. Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis;Current Oncology;2023-09-15

4. Therapeutic Antibodies in Medicine;Molecules;2023-09-05

5. Efficacy and safety of treatment with or without pertuzumab for HER2-positive breast cancer: A meta-analysis;Medicine;2023-06-02